Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 6/20 | 0.44 |
| ▸ | WNT1 | P04628 | 5/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 3/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11908797 | 0.93 | GSK3B (0.44) | DYRK1AWNT1ACHECHEK1NAMPT | |
| SCHEMBL473719 | 0.89 | BRAF (0.47) | DYRK1AWNT1ACHECHEK1PIM1 | |
| SCHEMBL11909390 | 0.89 | DYRK1A (0.46) | DYRK1AWNT1ACHECHEK1PIM1 | |
| SCHEMBL11909375 | 0.89 | DYRK1A (0.53) | DYRK1AWNT1ACHECHEK1PIM1 | |
| SCHEMBL1979171 | 0.85 | WNT1 (0.42) | DYRK1AWNT1CHRM4GSK3B | |
| SCHEMBL473695 | 0.85 | KDM4E (0.45) | DYRK1AWNT1ACHECHEK1 | |
| SCHEMBL473676 | 0.85 | CHEK1 (0.53) | DYRK1AWNT1ACHECHEK1 | |
| SCHEMBL3723196 | 0.85 | PIM1 (0.43) | DYRK1AACHECHEK1PIM1NAMPT | |
| SCHEMBL473778 | 0.85 | PIM1 (0.43) | DYRK1AACHECHEK1PIM1NAMPT | |
| SCHEMBL11908678 | 0.84 | PIM1 (0.52) | DYRK1AWNT1ACHECHEK1PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411389-A2 | 9H-PYRROLO[2,3-B: 5,4-C']DIPYRIDINE AZACARBOLINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-02-01 | — | — | EP | claimed |
| WO-2010109084-A2 | 9H-PYRROLO[2,3-B: 5,4-C'] DIPYRIDINE AZACARBOLINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | WO | claimed |
| US-20120208809-A1 | 9H-PYRROLO[2,3-B: 5,4-C'] DIPYRIDINE AZACARBOLINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-08-16 | — | — | US | disclosed |
| US-20120208809-A1 | 9H-PYRROLO[2,3-B: 5,4-C'] DIPYRIDINE AZACARBOLINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-08-16 | — | — | US | disclosed |
| US-20120208809-A1 | 9H-PYRROLO[2,3-B: 5,4-C'] DIPYRIDINE AZACARBOLINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-08-16 | — | — | US | disclosed |
| EP-2411389-A2 | 9H-PYRROLO[2,3-B: 5,4-C']DIPYRIDINE AZACARBOLINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010109084-A2 | 9H-PYRROLO[2,3-B: 5,4-C'] DIPYRIDINE AZACARBOLINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010109084-A2 | 9H-PYRROLO[2,3-B: 5,4-C'] DIPYRIDINE AZACARBOLINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208809-A1 | 9H-PYRROLO[2,3-B: 5,4-C'] DIPYRIDINE AZACARBOLINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | NPR3, CCNH, CBR3 | DYRK1A 3775/4885WNT1 3606/4885CHRM4 515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.